静脉内肿瘤(LR-TIV)与LI-RADS v2018:诊断特征、陷阱、预后与管理意义
本文阐述LI-RADS v2018中LR-TIV的诊断标准,强调区分肿瘤性癌栓与良性血栓对患者管理(如肝移植决策)的关键意义,并分析日常实践中的潜在陷阱及不确定病例的处理。
要点
- 识别静脉内肿瘤(TIV)可排除肝移植,需与良性血栓鉴别。
- LI-RADS v2017起将LR-TIV作为独立诊断类别,v2018延续。
- 肝硬化患者中其他肿瘤也可伴血管侵犯,需注意鉴别。
核心结论
- LR-TIV是LI-RADS v2018中的独立诊断类别,用于标识静脉内肿瘤性癌栓,其诊断需与良性血栓鉴别,并影响治疗决策。
研究设计与样本
- 本文为综述性文章,旨在讨论LR-TIV的诊断标准、潜在陷阱及不确定病例的管理,未涉及具体研究样本或设备。
关键影像表现/征象
- 原文未具体描述TIV的影像征象,但强调需根据LI-RADS v2018标准区分TIV与良性血栓。
诊断标准与关键数值
- LI-RADS v2018中LR-TIV的诊断标准为存在静脉内肿瘤癌栓,具体影像学标准未在摘要中详述。
临床应用与阅片要点
- 日常阅片需注意识别静脉内癌栓,避免将TIV误判为良性血栓,因其排除肝移植。
- 对肝硬化患者出现血管侵犯时,需考虑其他肿瘤可能,不局限于HCC。
- 对不确定病例应按LI-RADS v2018建议进行管理。
局限性
- 本文为综述,未提供原始研究数据,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Vascular invasion by hepatocellular carcinoma (HCC), also known as tumor in vein (TIV), indicates highly invasive tumor behavior and is also associated with poor outcome. Because a diagnosis of TIV precludes liver transplantation, knowledge of the imaging findings to differentiate between TIV and bland thrombus is key for proper patient management. Prior versions of liver imaging reporting and data system (LI-RADS) included presence of TIV as part of LR-5 criteria. However, even if HCC is the most common liver malignancy associated with TIV, other tumors can have vascular invasion and may occur in cirrhotic patients. For these reasons, in LI-RADS v2017 LR-TIV has been introduced as a new different diagnostic category. The aim of this article is to discuss the diagnostic criteria of LR-TIV according to LI-RADS v2018 and analyze potential pitfalls encountered on daily clinical practice. Indeterminate cases and how to manage them will also be discussed.
引用
- Catania R, Chupetlovska K, Borhani AA, et al. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY). 2021. PMID: 34519877. doi:10.1007/s00261-021-03270-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。